湖北省宏源药业科技股份有限公司董事会薪酬与考核委员 关于公司 2025 年限制性股票激励计划相关事项的 核查意见 湖北省宏源药业科技股份有限公司（以下简称"公司"）董事会薪酬与考核委 员会依据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和 国证券法》（以下简称"《证券法》"）《上市公司股权激励管理办法》（以下简 称"《管理办法》"）《深圳证券交易所创业板股票上市规则》（以下简称"《上 市规则》"）《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办 理》（以下简称"《自律监管指南 1 号》"）和《湖北省宏源药业科技股份有限公 司章程》（以下简称"《公司章程》"）等有关规定，对《湖北省宏源药业科技股 份有限公司 2025 年限制性股票激励计划（草案）》（以下简称"《激励计划（草 案）》"或"本次激励计划"）进行了核查，发表核查意见如下： 会 一、公司不存在《管理办法》规定的不得实行股权激励的以下情形： （一）最近一个会计年度财务会计报告被注册会计师出具否定意见或者无法 表示意见的审计报告； （二）最近一个会计年度财务报告内部控制被注册会计师出具否定意见或无 法表示意见的审计报告； （ ...

宏源药业公告，2025年上半年营业收入8.83亿元，同比下降1.73%。净亏损581.04万元，上年同期净利 润3580.96万元。 ...

湖北省宏源药业科技股份有限公司 2025 年半年度报告全文 湖北省宏源药业科技股份有限公司 2025 年半年度报告 2025 年 8 月 1 湖北省宏源药业科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人尹国平、主管会计工作负责人曾科峰及会计机构负责人(会计 主管人员)肖拥华声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公司 对任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的风 险认识，并且应当理解计划、预测与承诺之间的差异，敬请投资者注意投资 风险。 公司在本报告第三节"管理层讨论与分析"中"十、公司面临的风险和应 对措施"部分，具体描述了公司经营过程中可能存在的风险，敬请投资者关 注相关内容，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第二节 | 公司 ...

格隆汇8月19日丨宏源药业(301246.SZ)在互动平台表示，公司没有生产和销售电子氟化液。 ...

Core Viewpoint - The veterinary raw material drug market in China is expected to grow significantly, with a projected market size of approximately 185.1 billion yuan in 2024 and around 200 billion yuan in 2025, driven by increased demand and favorable economic conditions [1][8]. Industry Characteristics and Classification - Veterinary raw material drugs are pharmacologically active substances used directly in the manufacture of veterinary drug formulations, characterized by specificity, regulatory requirements, and high technical barriers [2][4]. - They can be classified by chemical properties into synthetic raw materials, biotechnological raw materials, and natural extracts, and by usage into antimicrobial drugs, antiparasitic drugs, antipyretic analgesics, and diagnostic/treatment aids [4][5]. Current Development Status - The veterinary drug industry in China has rapidly developed, becoming a significant part of the global veterinary drug market, with a projected market size of approximately 600 billion yuan in 2024 and 635 billion yuan in 2025 [6][8]. Market Size and Growth - The veterinary raw material drug market is expected to see a growth from 185.1 billion yuan in 2024 to 200 billion yuan in 2025, reflecting a recovery in demand and controlled supply [8][10]. Market Segmentation - Antimicrobial drugs dominate the veterinary raw material drug market, holding an 84% market share, while antiparasitic drugs account for about 11% [10]. Industry Chain - The industry chain includes upstream components such as basic chemical raw materials and intermediates, midstream production of raw materials through chemical synthesis and fermentation, and downstream processing into veterinary drug formulations for livestock and pet healthcare [12]. Competitive Landscape - The veterinary raw material drug industry in China has a low concentration level, with major companies including Haisheng Pharmaceutical, Qihui Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, among others [14][16]. - The industry is experiencing a shift towards larger, more capable firms as regulatory standards improve, leading to a potential increase in market concentration [14]. Key Enterprises - Guobang Pharmaceutical reported a revenue of 1.831 billion yuan from animal health raw materials in 2024, with a gross margin of 18.86% [16]. - Haisheng Pharmaceutical achieved a revenue of 112 million yuan from raw materials in 2024, with a gross margin of 36.28% [18]. Technology Development Trends - The production of raw materials and intermediates requires significant investment in research and development to improve process technology and compete in higher-margin sectors [20].

Core Insights - The oral hypoglycemic drug market is expanding rapidly due to the increasing prevalence of diabetes globally, with an estimated 589 million patients aged 20-79 by 2024, projected to reach 853 million by 2050 [4][6] - China has the highest number of diabetes patients at 148 million, accounting for 25% of the global total, with a significant rise in prevalence over the past 30 years [4][6] - The market for oral hypoglycemic drugs in China is expected to reach approximately 36.1 billion yuan by 2024, driven by both foreign and domestic companies [10][18] Industry Overview - Oral hypoglycemic drugs can be categorized into those that promote insulin secretion and those that lower blood sugar through other mechanisms [2][4] - The main classes of oral hypoglycemic drugs include sulfonylureas, meglitinides, DPP-4 inhibitors, GLP-1 receptor agonists, biguanides, TZDs, alpha-glucosidase inhibitors, and SGLT2 inhibitors [2][12] Market Dynamics - The oral hypoglycemic drug market in China is dominated by foreign companies such as AstraZeneca, MSD, and Bayer, which collectively hold over 50% market share [18] - The market is experiencing a shift with the rise of domestic companies, as they continue to innovate and develop new products [18][20] Recent Trends - The national centralized procurement policy has significantly impacted the pricing and availability of oral hypoglycemic drugs, with average price reductions reaching 88.5% in recent procurement rounds [15][16] - There is a growing trend towards the development of combination therapies and new mechanism drugs, such as glucose kinase activators and PPAR agonists, which are expected to become mainstream in diabetes treatment [20][22] Future Outlook - The DPP-4 inhibitors market is anticipated to expand further as domestic manufacturers increase their market penetration, potentially altering the current dominance of imported and generic drugs [20]

Core Viewpoint - The article highlights significant developments in the lithium battery industry, including major supply agreements, production expansions, and market price trends for key materials [3][4][5][6]. Group 1: Major Supply Agreements - LG Energy Solution has signed a six-year supply agreement with Chery Automobile for 8 GWh of 46-series cylindrical batteries, marking the first such contract between a Korean battery manufacturer and a Chinese automaker [3]. - Farasis Energy has begun supplying its 4680 cylindrical batteries to BMW for its global electric vehicle platform, with plans for increased production capacity at its facilities [4]. Group 2: Production and Investment Developments - Ruipai New Energy is nearing the completion of a project to produce 50,000 tons of lithium iron phosphate cathode materials, with the first production line expected to start by the end of June [5]. - Foshan Fospower Technology Group is acquiring Hebei Jinli New Energy Technology, with a total transaction value of 5.08 billion yuan [6]. Group 3: Lithium Material Market Conditions - The domestic lithium carbonate market price is hovering around 60,000 yuan per ton, with expectations of slight downward adjustments due to increased production and inventory digestion by downstream manufacturers [8][9]. - The price of ternary materials remains stable but may face reductions in July if new orders do not materialize [9][10]. - Phosphate lithium prices are stable, with significant production increases expected from companies like Fulin Precision Engineering [10][11]. Group 4: Battery and Electric Vehicle Market Trends - In June, domestic battery manufacturers are maintaining good production levels, with expectations for a slight decline in overall operating rates if no new projects arise [16]. - The sales of passenger vehicles reached 450,000 units, with new energy vehicle sales at 245,000 units, reflecting a year-on-year increase of 37.88% [18]. - Recent policy discussions in Hunan regarding energy storage pricing indicate a potential decline in competitive pricing for new projects [19].

特别提示： 1、根据《中华人民共和国公司法》（以下简称"公司法"）、《深圳证券 交易所上市公司自律监管指引第 9 号—回购股份》等相关规定，湖北省宏源药业 科技股份有限公司(以下简称"公司"或"本公司"）回购专用证券账户中的股 份 3,200,000 股不参与本次权益分派。本次权益分派将以公司现有总股本 400,006,800 股剔除回购专用证券账户中的股份 3,200,000 股后的股本 396,806,800 股为基数，向全体股东每 10 股派 0.30 元人民币现金（含税），实 际派发现金分红总额=396,806,800股×0.30元/10股=11,904,204.00元人民币。 证券代码：301246 证券简称：宏源药业 公告编号：2025-029 湖北省宏源药业科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 股为基数，向全体股东每 10 股派发现金股利 0.30 元人民币（含税），预计派发 现金股利人民币不超过 11,904,204 元（含税）。本次利润分配不以公积金转增 股本，不送红股，剩余未分配 ...

Financial Performance - The company's revenue and net profit are expected to show growth in Q2 2025 compared to Q1 2025, with current order volumes meeting expectations [1] - Direct exports to the U.S. account for a low percentage of revenue, minimizing the impact of recent U.S. tariffs [1] - The company has faced a significant decline in net profit since its IPO, with the stock price currently less than one-third of the initial offering price of 50 CNY per share [2][3] Market Challenges - The stock price has been in a long-term decline, attributed to macroeconomic factors, market conditions, and industry developments [2][3] - The company’s internal value does not align with its market capitalization, facing issues such as insufficient information disclosure and a lack of recognized business logic [3] Product Development - The solid-state battery project has completed kilogram-level experiments and is currently in the process optimization phase, with no mass production yet [2][4] - The company is focusing on high-end raw materials and specialty intermediates in the pharmaceutical sector, aiming to expand its international market presence [4] Strategic Initiatives - The company plans to enhance its core competitiveness through improved main business operations and effective value communication to investors [2][3] - In the lithium battery materials sector, the company aims to reduce production costs through technological upgrades and expansion into upstream supply chains [4]

湖北省宏源药业科技股份有限公司 关于参加湖北辖区上市公司 2025 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，湖北省宏源药业科技股份有限公司（以下 简称"公司"）将参加由湖北证监局、湖北省上市公司协会与深圳市全景网络有 限公司联合举办的"2025 年湖北辖区上市公司投资者集体接待日活动"，现将相 关事项公告如下： 证券代码：301246 证券简称：宏源药业 公告编号：2025-028 特此公告！ 湖北省宏源药业科技股份有限公司董事会 2025 年 6 月 6 日 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流，活动时间为 2025 年 6 月 12 日（星期四）14:00-16:40。届 时公司副董事长尹聃先生、财务负责人曾科峰先生、总监兼董事会秘书肖拥华先 生将在线就公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行 沟通与交流，欢迎广大投资者踊跃参 ...